Work

Abstract 791: CG'806, a first-in-class pan-FLT3/pan-BTK inhibitor, demonstrates superiority to other FLT3 and BTK inhibitors against primary patient samples

Year: 2018

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2018-791

Authors: Stephen E. Kurtz, Kevin Watanabe-Smith, Dan Bottomly, Beth Wilmot, Shannon Mcweeney, Andrea Local, Hongying Zhang, Stephen Howell, William Rice, Brian J. Druker, Jeffrey W. Tyner

Institutions: Oregon Health & Science University, Aptose Biosciences (United States), University of California San Diego, Moores Cancer Center, OHSU Knight Cancer Institute

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2887235898

Cites:

Cited by:

Related to: 10